<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39239035</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-0801</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of medicine and surgery (2012)</Title><ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation></Journal><ArticleTitle>MEIBO (perfluorohexyloctane): a novel approach to treating dry eye disease.</ArticleTitle><Pagination><StartPage>5292</StartPage><EndPage>5298</EndPage><MedlinePgn>5292-5298</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MS9.0000000000002322</ELocationID><Abstract><AbstractText>Dry eye disease (DED) or keratoconjunctivitis sicca (KCS) is a multifactorial disease that classically develops due to the hyperosmolarity of the tear film. Categorically divided into two types, based on decreased production and increased evaporation of the tear film, DED begins with a spectrum of nonspecific symptoms like pruritus, redness, burning and discomfort, progressively leading to stringy mucus eye discharge, photophobia, twitching, visual fluctuations, and punctate epithelial lesions. This disease has numerous treatment options, including medications, artificial tear inducers, and surgical manoeuvres that prevent water loss from the tear film. However, each of these treatment options has its limitations. The Food and Drug Administration (FDA) has approved another intervention, Meibo (perfluorohexyloctane), as a choice of management for dry eye disease. With its shielding action on the ocular surface, Meibo (perfluorohexyloctane) reduces desiccation stress-induced ocular damage, making it highly specific for treating DED. Available in an eye drop formulation of perfluorohexyloctane (PFHO), these drops can reduce saline evaporation by up to 80%. The methods we used for this analysis are literature searches from PubMed, Medline and Google Scholar. This study aims to scour varying differentials of DED, its aetiology, general interventions, the latest refinements, and clinical efficacy, safety, and trials associated with Meibo (perfluorohexyloctane) in the management of DED.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Azhar</LastName><ForeName>Ayesha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taimuri</LastName><ForeName>Muskan A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oduoye</LastName><ForeName>Malik Olatunde</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>The Medical Research Circle, Gisenyi, Goma, Democratic Republic of Congo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sumbal</LastName><ForeName>Anusha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Ayesha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Amna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>Areeba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waqar</LastName><ForeName>Eisha</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med Surg (Lond)</MedlineTA><NlmUniqueID>101616869</NlmUniqueID><ISSNLinking>2049-0801</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Food and Drug Administration</Keyword><Keyword MajorTopicYN="N">Meibo (perfluorohexyloctane)</Keyword><Keyword MajorTopicYN="N">dry eye disease</Keyword><Keyword MajorTopicYN="N">keratoconjunctivitis sicca</Keyword><Keyword MajorTopicYN="N">perfluorohexyloctane</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare that are relevant to the content of this article.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>4</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39239035</ArticleId><ArticleId IdType="pmc">PMC11374244</ArticleId><ArticleId IdType="doi">10.1097/MS9.0000000000002322</ArticleId><ArticleId IdType="pii">AMSU-D-23-02367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mohamed HB, Abd El-Hamid BN, Fathalla D, et al. . Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharm Sci 2022;175:106206.</Citation><ArticleIdList><ArticleId IdType="pubmed">35568107</ArticleId></ArticleIdList></Reference><Reference><Citation>Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. DeutschesArzteblattinternational 2015;112:71–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335585</ArticleId><ArticleId IdType="pubmed">25686388</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaumberg DA, Sullivan DA, Buring JE, et al. . Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318–326.</Citation><ArticleIdList><ArticleId IdType="pubmed">12888056</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzmán M, Miglio M, Keitelman I, et al. . Transient tear hyperosmolarity disrupts the neuroimmune homeostasis of the ocular surface and facilitates dry eye onset. Immunology 2020;161:148–161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496787</ArticleId><ArticleId IdType="pubmed">32702135</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemanová M. Dry eye disease. A review. Syndrom suchého oka. Přehled. Ceska a slovenskaoftalmologie :casopis Ceske oftalmologickespolecnosti a Slovenskeoftalmologickespolecnosti 2021;77:107–119.</Citation><ArticleIdList><ArticleId IdType="pubmed">34107689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang AC, Singh S, Craig JP, et al. . Omega-3 fatty acids and eye health: opinions and self-reported practice behaviors of optometrists in Australia and New Zealand. Nutrients 2020;12:1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7230711</ArticleId><ArticleId IdType="pubmed">32331489</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Robles JG, Pérez Vázquez AK, Navas A, et al. . Safety and efficacy of pilocarpine, cevimeline, and diquafosol compared to artificial tears for the treatment of dry eye: protocol for a systematic review. Syst Rev 2022;11:105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9148479</ArticleId><ArticleId IdType="pubmed">35643581</ArticleId></ArticleIdList></Reference><Reference><Citation>Frampton JE. Varenicline solution nasal spray: a review in dry eye disease. Drugs 2022;82:1481–1488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9533262</ArticleId><ArticleId IdType="pubmed">36197638</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Carreno-Galeano JT, Singh RB, et al. . Long-term outcomes of punctal cauterization in the management of ocular surface diseases. Cornea 2021;40:168–171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704919</ArticleId><ArticleId IdType="pubmed">32467449</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration , 2023, NDA 216675 Pages 5-10. Accessed, 9th August, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216675s000lbl.pdf</Citation></Reference><Reference><Citation>Vittitow J, Kissling R, DeCory H, et al. . In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. Curr Ther Res Clin Exp 2023;98:100704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10300294</ArticleId><ArticleId IdType="pubmed">37389230</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidl D, Bata AM, Szegedi S, et al. . Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocular Pharmacol Therap 2020;36:154–161.</Citation><ArticleIdList><ArticleId IdType="pubmed">31895638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauber J Berdy GJ Wirta DL et al. . GOBI Study Group . NOV03 for Dry Eye Disease Associated with Meibo (perfluorohexyloctane)mian Gland Dysfunction: results of the Randomized Phase 3 GOBI Study. Ophthalmology 2023;130:516–524.</Citation><ArticleIdList><ArticleId IdType="pubmed">36574848</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudouin C, Messmer EM, Aragona P, et al. . Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of Meibo (perfluorohexyloctane)mian gland dysfunction. Br J Ophthalmol 2016;100:300–306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789719</ArticleId><ArticleId IdType="pubmed">26781133</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard JD Kurata F Epitropoulos AT et al. . MOJAVE Study Group . NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibo (perfluorohexyloctane)mian Gland Dysfunction: the Randomized Phase 3 MOJAVE Study. Am J Ophthalmol 2023;252:265–274.</Citation><ArticleIdList><ArticleId IdType="pubmed">36948372</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L, Gao Z, Zhu L, et al. . Perfluorohexyloctane eye drops for dry eye disease associated with Meibo (perfluorohexyloctane)mian gland dysfunction in Chinese patients. JAMA Ophthalmol 2023;141:385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10020931</ArticleId><ArticleId IdType="pubmed">36929413</ArticleId></ArticleIdList></Reference><Reference><Citation>Habbe KJ, Frings A, Saad A, et al. . The influence of a mineral oil cationic nanoemulsion or perfluorohexyloctane on the tear film lipid layer and higher order aberrations. PLoS One 2023;18:e0279977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847907</ArticleId><ArticleId IdType="pubmed">36652431</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauber J Wirta DL Sall K et al. . SEECASE Study Group . A randomized clinical study (SEE CASE) to assess the efficacy, safety, and tolerability of NOV03 for the treatment of dry eye disease. Cornea 2021;40:1132–1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8330824</ArticleId><ArticleId IdType="pubmed">33369937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L, Gao Z, Zhu L, et al. . Perfluorohexyloctane eye drops for dry eye disease associated with Meibo (perfluorohexyloctane)mian gland dysfunction in Chinese patients: a randomized clinical trial. JAMA Ophthalmol 2023;141:385–392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10020931</ArticleId><ArticleId IdType="pubmed">36929413</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal P, Khun D, Krösser S, et al. . Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. Ocul Surf 2019;17:241–249.</Citation><ArticleIdList><ArticleId IdType="pubmed">30831252</ArticleId></ArticleIdList></Reference><Reference><Citation>Steven P, Augustin AJ, Geerling G, et al. . Semifluorinated alkane eye drops for treatment of dry eye disease due to meibo (perfluorohexyloctane)mian gland disease. J Ocular Pharmacol Therap 2017;33:678–685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655475</ArticleId><ArticleId IdType="pubmed">28922088</ArticleId></ArticleIdList></Reference><Reference><Citation>Steven P, Scherer D, Krösser S, et al. . Semifluorinated alkane eye drops for treatment of dry eye disease-a prospective, multicenter noninterventional study. J Ocular Pharmacol Therap 2015;31:498–503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4599377</ArticleId><ArticleId IdType="pubmed">26296040</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>